Recurrent glomerular disease in the allograft: Risk factors and management

Chronic Allograft Failure: Natural History, Pathogenesis, Diagnosis and Management

Volumn , Issue , 2008, Pages 200-221

  Wadei, Hani M ^a   Geiger, Xochiquetzal J ^a   Mai, Martin L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84858208822     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781498712729-35     Document Type: Chapter

References (284)

1. Cohen DJ, St Martin L, Christensen LL et al. Kidney and Pancreas Transplantation in the United States, 1995-2004. Am J Transplant 2006; 6(5p2):1153-69.
2. Morzycka M, Croker BP Jr., Sieglcr HF et al. Evaluation of recurrent glomerulonephritis in kidney allografts. Am J Med 1982; 72(4):588-98.
3. Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation 1997; 63(8):1045-52.
4. Briganti EM, Russ GR, McNeil JJ et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347(2):103-9.
5. Hariharan S, Adams MB, Brennan DC et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68(5):635-4l.
6. Briggs JD, Jones E. Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14(3):564-65.
7. Hariharan S, Peddi VR, Savin VJ et al. Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. Am J Kidney Dis 1998; 31(6):928-31.
8. Odorico JS, Knechde SJ, Rayhill SC et al. The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis. Transplantation 1996; 61(2):228-34.
9. Andresdottir MB, Hoitsma AJ, Assmann KJ et al. The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Transplantation 1999; 68(5);623-27.
10. Ibrahim H, Rogers T, Casingal V et al. Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 2006; 81(2):214-19.
11. Vongwiwatana A, Gourishankar S, Campbell PM et al. Peritubular Capillary Changes and C4d Deposits Are Associated with Transplant Glomerulopathy But Not IgA Nephropathy. Am J Transplant 2004; 4(1): 124-29.
12. Sturdevant M, Garcia-Roca R, Nguyen T et al. Recurrent disease after kidney transplant—little progress in 2 decades. Transplantation 2006; 82(1 Suppl 2): 167-68.
13. Myslak M, Amer H, Morales P et al. Interpreting posttransplant proteinuria in patients with proteinuria pretransplant. Am J Transplant 2006; 6(7):1660-65.
14. The 13th report of the human renal transplant registry. Transplant Proc 1977; 9(1):9-26.
15. Odum J, Peh CA, Clarkson AR et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 1994; 9(3):309-12.
16. Wang AYM, Lai FM, Yu AW-Y et al. Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 2001; 38(3):588-96.
17. Frohnert PP, Donadio JV Jr., Velosa JA et al. The fate of renal transplants in patients with IgA nephropathy. Clin Transplant 1997; 11(2):127-33.
18. Namba Y, Oka K, Moriyama T et al. Risk factors for graft loss in patients with recurrent IGA nephropathy after renal transplantation. Transplant Proc 2004; 36(5):1314-16.
19. Ponticelli C, Traversi L, Feliciani A et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60(5):l948-54.
20. Chandrakantan A, Ratanapanichkich P, Said M et al. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. Nephrol Dial Transplant 2005; 20(6):1214-21.
21. McDonald SP, Russ GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 2006; 82(6):759-762.
22. Freese P, Svalander C, Norden G et al. Clinical risk factors for recurrence of IgA nephropathy. Clin Transplant 1999; 13(4):313-17.
23. Coppo R, Amore A, Cirina P et al. IgA serology in recurrent and nonrecurrent IgA nephropathy after renal transplantation. Nephrol Dial Transplant 1995; 10(12):2310-15.
24. Kessler M, Hiesse C, Hestin D et al. Recurrence of immunoglobulin a nephropathy after renal transplantation in the cyclosporine era. Am J Kidney Dis 1996; 28(1):99-104.
25. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61(3):1098-14.
26. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349(9054):774.
27. Ji S, Liu M, Chen J et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. Clin Transplant2004; l8(5):536-40.
28. Tolkoff-Rubin NE, Cosimi AB, Fuller T et al. IGA nephropathy in HLA-identical siblings. Transplantation 1978; 26(6):430-33.
29. Moriyama X Nitta K, Suzuki K et al. Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant 2005; 19 Suppl 14:41-48.
30. Suzuki K, Honda K, Tanabe K et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63(6):2286-94.
31. Kim YS, Moon JI, Jeong HJ et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation 2001; 71(2):233-38.
32. Andresdottir MB, Hoitsma AJ, Assmann KJ et al. Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol2001; 56(4):279-88.
33. Choy BY, Chan TM, Lo SK et al. Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol. Dial. Transplant 2003; 18(11):2399-404.
34. Soler MJ, Mir M, Rodriguez E et al. Recurrence of IgA Nephropathy and Henoch-Schonlein Purpura After Kidney Transplantation: Risk Factors and Graft Survival. Transplant Proc 2005; 37(9):3705-9.
35. Bumgardner GL, Amend WC, Ascher NL et al. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation1998; 65(8):1053-60.
36. Ohmacht C, Kliem V, Burg M et al. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation 1997; 64(10): 1493-96.
37. Jeong HJ, Hong SW, Kim YS et al. Histologic factors associated with nephrotic-range proteinuria in recurrent IGA nephropathy. Transplant Proc 2003; 35(1):291.
38. Oka K, Imai E, Moriyama T et al. A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant 2000; 15(5):689-95.
39. Toki K, Oka K, Kyo M et al. Clinicopathologic evaluation of IgA nephropathy in renal transplant recipients. Transplant Proc 2001; 33(X2):1249-53.
40. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14(6): 1578-83
41. Courtney AE, McNamee PT, Nelson WE et al. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 2006; 21(12):3550-54.
42. Meulders Q, Pirson Y, Cosyns JP et al. Course of Henoch-Schonlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation 1994; 58(11):1179-86.
43. Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23(2):172-82.
44. DalTAmico R, Ghiggeri G, Carraro M et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34(6): 1048-55.
45. Banfi G, Colturi C, Montagnino G et al. The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation 1990; 50(4):594-96.
46. Artero M, Biava C, Amend W et al. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992; 92(4):375-83.
47. Pardon A, Audard V, Caillard S et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006; 21(4):1053-59.
48. Wuhl E, Fydryk J, Wiesel M et al. Impact of recurrent nephrotic syndrome after renal transplantation in young patients. Pediatr Nephrol 1998; 12(7):529-33.
49. Senggutuvan P, Cameron JS, Hartley RB et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4(1):21-28.
50. Ingulli E, Tejani A. Incidence, treatment and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children—a single-center experience. Transplantation 1991; 51(2):401-5.
51. Zimmerman CE. Renal transplantation for focal segmental glomerulosclerosis. Transplantation 1980; 29(2):172.
52. Baum MA, Stablein DM, Panzarino VM et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59(1):328-33.
53. Abbott KC, Sawyers ES, Oliver JD III et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37(2):366-73.
54. Cibrik DM, Kaplan B, Campbell DA et al. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 2003; 3(l):64-67.
55. First MR. Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. Pediatr Nephrol 1995; 9 Suppl:S40-42.
56. Raafat R, Travis LB, Kalia A et al. Role of transplant induction therapy on recurrence rate of focal segmental glomerulosclerosis. Pediatr Nephrol2000; l4(3):189-94.
57. Hubsch H, Montane B, Abitbol C et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol 2005; 20(2):210-16.
58. Boardman R, Trofe J, Alloway R et al. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. Transplant Proc 2005; 37(2):817-18.
59. Deegens JK, Wetzels JF. Treatment of recurrent focal glomerulosclerosis after renal transplantation: is prednisone essential to maintain a sustained remission? Transplantation 2003; 75(7):1080-81.
60. Hocker B, Knuppel T, Waldherr R et al. Recurrence of proteinuria 10 years posttransplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol2006; 21(10):l476-79.
61. Dantal J, Baatard R, Hourmant M et al. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 1991; 52(5):827-31.
62. Kim EM, Striegel J, Kim Y et al. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994; 45(5): 1440-45.
63. Wetzels JF. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5(10):2594; author reply 2595.
64. Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 1984; 22(1):32-38.
65. Kemper MJ, Wolf G, Muller-Wiefel DE. Transmission of Glomerular Permeability Factor from a Mother to Her Child. N Engl J Med 2001; 344(5):386-87.
66. Sharma M, Sharma R, McCarthy ET et al. “The FSGS factor:” enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10(3):552-61.
67. Le Berre L, Godfrin Y, Lafond-Puyet L et al. Effect of plasma fractions from patients with focal and segmental glomerulosclerosis on rat proteinuria. Kidney Int 2000; 58(6):2502-11.
68. Sharma M, Sharma R, McCarthy ET et al. The Focal Segmental Glomerulosclerosis Permeability Factor: Biochemical Characteristics and Biological Effects. Exp Biol Med 2004; 229(1):85-98.
69. McCarthy ET, Sharma M. Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney hit 2002; 61(2):534-41.
70. Sharma R, Sharma M, McCarthy ET et al. Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 2000; 58(5): 1973-79.
71. Candiano G, Musante L, Carraro M et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12(1):143-50.
72. Godfrin Y, Dantal J, Perretto S et al. Study of the in vitro effect on glomerular albumin permselectivity of serum before and after renal transplantation in focal segmental glomerulosclerosis. Transplantation 1997; 64(12):1711-15.
73. Dantal J, Godfrin Y, Koll R et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 1998; 9(9):1709-15.
74. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334(14):878-83.
75. Coward RJM, Foster RR, Patton D et al. Nephrotic Plasma Alters Slit Diaphragm-Dependent Signaling and Translocates Nephrin, Podocin and CD2 Associated Protein in Cultured Human Podocytes. J Am Soc Nephrol 2005; 16(3):629-37.
76. Karle SM, Uetz B, Ronner V et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13(2):388-93.
77. Weber S, Gribouval O, Esquivel EL et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low posttransplant recurrence. Kidney Int 2004; 66(2):571-79.
78. Bertelli R, Ginevri F, Caridi G et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41(6):1314-21.
79. Becker-Cohen R, Bruschi M, Rinat C et al. Recurrent Nephrotic Syndrome in Homozygous Truncating NPHS2 Mutation Is Not Due to AntiPodocin Antibodies. Am J Transplant 2006; 15:15.
80. Carraro M, Caridi G, Bruschi M et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13(7): 1946-52.
81. Gohh RY, Yango AF, Morrissey PE et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5(12):2907-12.
82. Artero ML, Sharma R, Savin VJ et al. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23(4):574-81.
83. Pradhan M, Petro J, Palmer J et al. Early use of plasmapheresis for recurrent posttransplant FSGS. Pediatr Nephrol 2003; 18(9):934-38.
84. Davenport RD. Apheresis treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation: re-analysis of published case-reports and case-series. J Clin Apher 2001; 16(4):175-78.
85. Belson A, Yorgin PD, Al-Uzri AY et al. Long-term plasmapheresis and protein A column treatment of recurrent FSGS. Pediatr Nephrol 2001; 16(12):985-89.
86. Deegens JK, Andresdottir MB, Croockewit S et al. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004; 17(3): 151-57.
87. Dantal J, Bigot E, Bogers W et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330(1):7-14.
88. Kershaw DB, Sedman AB, Kelsch RC et al. Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 1994; 8(6):546-49.
89. Vincenti F, Biava C, Tomlanovitch S et al. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation 1989; 47(4):595-98.
90. Raafat RH, Kalia A, Travis LB et al. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004; 44(1):50-56.
91. Srivastava RN, Kalia A, Travis LB et al. Prompt remission of postrenal transplant nephrotic syndrome with high-dose cyclosporine. Pediatr Nephrol 1994; 8(1):94-95.
92. Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003; 75(6):810-14.
93. Sharma R, Savin VJ. Cyclosporine prevents the increase in glomerular albumin permeability caused by serum from patients with focal segmental glomerular sclerosis. Transplantation 1996; 61(3):381-83.
94. Sharma R, Sharma M, Ge X et al. Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular cAMP. Transplantation 1996; 62(12):1916-20.
95. Hristea D, Hadaya K, Marangon N et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20(1):102-5.
96. Ramos EL. Recurrent diseases in the renal allograft. J Am Soc Nephrol1991; 2(2):109-21.
97. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996; 101(1):100-7.
98. Moroni G, Tantardini F, Gallelli B et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005; 45(5):903-11.
99. Stone JH, Millward CL, Olson JL et al. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998; 41(4):678-86.
100. Nyberg G, Karlberg I, Svalandcr C et al. Renal transplantation in patients with systemic lupus erythematosus: increased risk of early graft loss. Scand J Urol Nephrol 1990; 24(4):307-13.
101. Goral S, Ynares C, Shappell SB et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75(5):651-56.
102. Nyberg G, Blohme I, Persson H et al. Recurrence of SLE in transplanted kidneys: a follow-up transplant biopsy study. Nephrol Dial Transplant1992; 7(11):1116-23.
103. Lochhead KM, Pirsch JD, DAlessandro AM et al. Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney Int1996; 49(2):512-17.
104. Azevedo LS, Romao JE Jr., Malheiros D et al. Renal transplantation in systemic lupus erythematosus. A case control study of 45 patients. Nephrol Dial Transplant 1998; 13(11):2894-98.
105. Zara CP, Lipkowitz GS, Perri N et al. Renal transplantation and end-stage lupus nephropathy in the cyclosporine and prccyclosporine eras. Transplant Proc 1989; 21(1 Pt 2):1648-51.
106. Sfikakis PP, Bolctis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52(2):501-13.
107. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum2002; 46(10):2673-77.
108. Smith KG, Jones RB, Bums SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse and retreatment. Arthritis Rheum 2006; 54(9):2970-82.
109. Ferraris JR, Ramirez JA, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr Nephrol 2002; 17(10):809-14.
110. Artz MA, Steenbetgen EJ, Hoitsma AJ et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76(5):821-26.
111. Kaplan BS, Papadimitriou M, Brezin JH et al. Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome. Am J Kidney Dis 1997; 30(6):760-65.
112. Lahlou A, Lang P, Charpentier B et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de rile-de-France (GCIF). Medicine (Baltimore) 2000; 79(2):90-102.
113. Miller RB, Burke BA, Schmidt WJ et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 1997; 12(7): 1425-30.
114. Conlon PJ, Brennan DC, Pfaf W et al. Renal transplantation in adults with thrombotic thrombocytopenic purpura/haemolytic-uraemic syndrome. Nephrol Dial Transplant 1996; 11(9):1810-14.
115. Bresin E, Daina E, Noris M et al. Outcome of Renal Transplantation in Patients with nonShiga Toxin-Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clin J Am Soc Nephrol2006; 1(1):88-99.
116. Remuzzi G, Ruggenenti P, Colledan M et al. Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. Am J Transplant 2005; 5(5):1146-50.
117. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment and outcome. Blood 2006; 108(4):1267-79.
118. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17(7):2017-25.
119. Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Nad Acad Sci USA 2003; 100(22): 12966-71.
120. Ducloux D, Rebibou JM, Semhoun-Ducloux S et al. Recurrence of hemolytic-urcmic syndrome in renal transplant recipients: a meta-analysis. Transplantation 1998; 65(10):l405-7.
121. Florman S, Benchimol C, Lieberman K et al. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatr Transplant 2002; 6(4):352-55.
122. Bergstein J, Michael A Jr., Kellstrand C et al. Hemolytic-uremic syndrome in adult sisters. Transplantation 1974; 17(5):487-90.
123. Donne RL, Abbs I, Barany P et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002; 40(6):E22.
124. Olie KH, Florquin S, Groothoff JW et al. Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatr Nephrol 2004; 19(10):1173-76.
125. Noris M, Remuzzi G. Hemolytic Uremic Syndrome. J Am Soc Nephrol 2005; 16(4): 1035-1050.
126. Olie KH, Goodship TH, Verlaak R et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 2005; 45(1):e12-15.
127. Yassa SK, Blessios G, Marinides G et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19(3):423-26.
128. Banerjee D, Kupin W, Roth D. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol 2003; 16(5):733-35.
129. Saland JM, Emre SH, Shneider BL et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006; 6(8):1948-52.
130. Remuzzi G, Ruggenenti P, Codazzi D et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. The Lancet2002; 359(9318):1671-72.
131. Cheong HI, Lee BS, Kang HG et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004; 19(4):454-58.
132. Couchoud C, Pouteil-Noble C, Colon S et al. Recurrence of membranous nephropathy after renal transplantation. Incidence and risk factors in 1614 patients. Transplantation 1995; 59(9):1275-79.
133. Marcen R, Mampaso F, Teruel JL et al. Membranous nephropathy: recurrence after kidney transplantation. Nephrol Dial Transplant 1996; 11(6): 1129-33
134. Berger BE, Vincenti F, Biava C et al. De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation 1983; 35(4):315-19.
135. Hariharan S, Savin VJ. Recurrent and de novo disease after renal transplantation: a report from the Renal Allograft Disease Registry. Pediatr Transplant 2004; 8(4):349-50.
136. O’Meara Y, Green A, Carmody M et al. Recurrent glomerulonephritis in renal transplants: fourteen years’ experience. Nephrol Dial Transplant1989; 4(8):730-34.
137. Schwarz A, Krause PH, Offermann G et al. Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis 1991; 17(5):524-31.
138. Ronco P, Allegri L, Brianti E et al. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology. Appl Pathol 1989; 7(2):85-98.
139. Ronco PM, Ardaillou N, Verroust P et al. Pathophysiology of the podocyte: a target and a major player in glomerulonephritis. Adv Nephrol Necker Hosp 1994; 23:91-131.
140. Kerjaschki D, Horvat R, Binder S et al. Identification of a 400-kd protein in the brush borders of human kidney tubules that is similar to gp330, the nephritogenic antigen of rat Heymann nephritis. Am J Pathol 1987; 129(1):183-91.
141. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 1996; 7(12):2518-26.
142. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis due to antineutral endopeptidase antibodies. N Engl J Med 2002; 346(26):2053-60.
143. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis with vascular injury induced by antineutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. J Am Soc Nephrol 2003; 14 Suppl 1:S27-32.
144. Debiec H, Nauta J, Coulet F et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364(9441):1252-59.
145. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004; 364(9441): 1194-96.
146. Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 2006; 15(3):258-63.
147. Josephson MA, Spargo B, Hollandsworth D et al. The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. Am J Kidney Dis 1994; 24(5):873-78.
148. Davison AM, Johnston PA. Allograft membranous nephropathy. Nephrol Dial Transplant 1992; 7 Suppl 1:114-18.
149. Poduval RD, Josephson MA, Javaid B. Treatment of de novo and recurrent membranous nephropathy in renal transplant patients. Semin Nephrol2003; 23(4):392-99.
150. Cosyns JP, Couchoud C, Pouteil-Noble C et al. Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol 1998; 50(3):l44-53.
151. Monga G, Mazzucco G, Basolo B et al. Membranous glomerulonephritis (MGN) in transplanted kidneys: morphologic investigation on 256 renal allografts. Mod Pathol 1993; 6(3):249-58.
152. Truong L, Gelfand J, D’Agati V et al. De novo membranous glomerulo-nephropathy in renal allografts: a report of ten cases and review of the literature. Am J Kidney Dis 1989; l4(2):131-44.
153. Schwarz A, Krause PH, Offermann G et al. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation 1994; 58(6):650-54.
154. Kowalewska J, Smith KD, Hudkins KL et al. Membranous glomerulopathy with spherules: an uncommon variant with obscure pathogenesis. Am J Kidney Dis 2006; 47(6):983-92.
155. Lazowski P, Sablay LB, Glicklich D. Recurrent crescentic membranous nephropathy in two successive renal transplants: association with choroidal effusions and retinal detachment. Am J Nephrol 1998; 18(2):146-50.
156. Hill GS, Robertson J, Grossman R et al. An unusual variant of membranous nephropathy with abundant crescent formation and recurrence in the transplanted kidney. Clin Nephrol 1978; 10(3): 114-20
157. Antignac C, Hinglais N, Gubler MC et al. De novo membranous glomerulonephritis in renal allografts in children. Clin Nephrol 1988; 30(1):1-7.
158. Honkanen E, Tomroth T, Pettersson E et al. Glomerulonephritis in renal allografts: results of 18 years of transplantations. Clin Nephrol 1984; 21(4):210-19.
159. Nakazawa K, Shimojo H, Komiyama Y et al. Preexisting membranous nephropathy in allograft kidney. Nephron 1999; 81(1):76-80.
160. Parker SM, Pullman JM, Khauli RB. Successful transplantation of a kidney with early membranous nephropathy. Urology 1995; 46(6):870-72.
161. Freese PM, Svaiander CT, Moine J et al. Renal allograft glomerulopathy and the value of immunohistochemistry. Clin Nephrol 2004; 62(4):279-86.
162. Lieberthal W, Bernard DB, Donohoe JF et al. Rapid recurrence of membranous nephropathy in a related allograft. Clin Nephrol 1979; 12(5):222-228.
163. Obermiller LE, Hoy WE, Eversole M et al. Recurrent membranous glomerulonephritis in two renal transplants. Transplantation 1985; 40(1):100-2.
164. Heidet L, Gagnadoux ME, Beziau A et al. Recurrence of de novo membranous glomerulonephritis on renal grafts. Clin Nephrol 1994; 41(5):314-18.
165. Mathew TH. Recurrence of disease following renal transplantation. Am J Kidney Dis 1988; 12(2):85-96.
166. Andresdottir M, Hoitsma A, Wetzels J. Donor characteristics as risk factors for recurrence of membranous nephropathy after renal transplantation. Am J Transplant 2006; 6(52):947.
167. Agarwal SK, Dash SC, Mehta SN et al. Recurrence of idiopathic membranous nephropathy in HLA-identical allograft. Nephron 1992; 60(3):366.
168. First MR, Vaidya PN, Maryniak RK et al. Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation 1984; 38(6):607-12.
169. Lai S, Luger A, Hashefi M et al. De novo membranous glomerulopathy in an renal transplant patient treated with FK 506. The first reprted case. IntJ Artif Organs 1997; 20(7):379-82.
170. Montagnino G, Colturi C, Banfi G et al. Membranous nephropathy in cyclosporine-treated renal transplant recipients. Transplantation 1989; 47(4):725-27.
171. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6(11):2535-42.
172. Ideura T, Hora K, Kaneko Y et al. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report. Transplant Proc 2000; 32(1):223-26.
173. Johnston PA, Goode NP, Aparicio SR et al. Membranous allograft nephropathy. Remission of nephrotic syndrome with pulsed méthylprednisolone and high-dose alternate-day steroids. Transplantation 1993; 55(1):214-16.
174. Innés A, Woodrow G, Boyd SM et al. Recurrent membranous nephropathy in successive renal transplants. Nephrol Dial Transplant 1994; 9(3):323-25.
175. Dantal J, Giral M, Hoormant M et al. Glomerulonephritis recurrences after kidney transplantation. Curr Opin Nephrol Hypertens 1995; 4(2):l46-54.
176. Harzallah K, Badid C, Fouque D et al. Efficacy of mycophenolate mofetil on recurrent glomerulonephritis after renal transplantation. Clin Nephrol 2003; 59(3):212-16.
177. Gallon L, Chhabra D. AntiCD20 Monoclonal Antibody (Rituximab) for the Treatment of Recurrent Idiopathic Membranous Nephropathy in a Renal Transplant Patient. Am J Transplant 2006; 6(12):3017-21.
178. Little MA, Dupont P, Campbell E et al. Severity of primary MPGN, rather than MPGN type, determines renal survival and posttransplantation recurrence risk. Kidney Int 2006; 69(3):504-11.
179. Andresdottir MB, Assmann KJ, Hoitsma AJ et al. Recurrence of type I membranoproliferative glomerulonephritis after renal transplantation: analysis of the incidence, risk factors and impact on graft survival. Transplantation 1997; 63(11):1628-33.
180. Karakayali FY, Ozdemir H, Kivrakdal S et al. Recurrent glomerular diseases after renal transplantation. Transplant Proc 2006; 38(2):470-72.
181. Shimizu T, Tanabe K, Oshima T et al. Recurrence of membranoproliferative glomerulonephritis in renal allografts. Transplant Proc 1998; 30(7):3910-13.
182. Cameron JS. Glomerulonephritis in renal transplants. Transplantation1982; 34(5);237-45.
183. Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am J Kidney Dis 1994; 24(1):142-54.
184. Brunkhorst R, Kliem V, Koch KM. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996; 72(3):465-67.
185. Roth D, Cirocco R, Zucker K.et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995; 59(12):l676-82.
186. Cosio FG, Roche Z, Agarwal A et al. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996; 28(5):752-58.
187. Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med1993; 328(7):465-70.
188. Madala ND, Naicker S, Singh B et al. The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 2003; 60(2):69-73.
189. Ohsawa I, Ohi H, Endo M et al. High prevalence of hepatitis C virus antibodies in older patients with membranoproliferative glomerulonephritis. Nephron 1999; 82(4):366-67.
190. Sabry AA, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002; 17(2):239-45.
191. Yamabe H, Johnson RJ, Gretch DR et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol1995; 6(2):220-23.
192. Andresdottir MB, Assmann KJ, Hilbrands LB et al. Primary £p-stein-Barr virus infection and recurrent type I membranoproliferative glomerulonephritis after renal transplantation. Nephrol Dial Transplant2000; 15(8): 1235-37.
193. Berthoux P, Laurent B, Cecillon S et al. Membranoproliferative glomerulonephritis with subendothelial deposits (type 1) associated with hepatitis G virus infection in a renal transplant recipient. Am J Nephrol 1999; 19(4):513-18.
194. Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol 1997; 8(11):1801-08.
195. Andresdottir MB, Assmann KJ, Hilbrands LB et al. Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection? Am J Kidney Dis 2000; 35(2):E6.
196. Andresdottir MB, Assmann KJ, Koene RA et al. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998; 32(4):582-88.
197. Cheigh JS, Mouradian J, Susin M et al. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980; 18(3) 358-65.
198. Muczynski KA. Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. Am J Nephrol 1995; 15(5):446-49.
199. Curtis JJ, Wyatt RJ, Bhathena D et al. Renal transplantation for patients with type I and type II membranoproliferative glomerulonephritis: serial complement and nephritic factor measurements and the problem of recurrence of disease. Am J Med 1979; 66(2): 216-25.
200. Dwyer K, Hill P, Murphy B. Early recurrence of type 1 membranoproliferative glomerulonephritis following cadaveric renal transplantation. Aust N Z J Med 2000; 30(1):103-110.
201. Habib R, Zurowska A, Hinglais N et al. A specific glomerular lesion of the graft: allograft glomerulopathy. Kidney Int Suppl 1993; 42: S104-11.
202. Maryniak RK, First MR, Weiss MA. Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int 1985; 27(5):799-806.
203. Cameron JS, Turner DR, Heaton J et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983: 74(2): 175-92.
204. Hamburger J, Crosnier J, Noel LH. Recurrent glomerulonephritis after renal transplantation. Annu Rev Med 1978; 29:67-72.
205. Cameron JS, Turner DR. Recurrent glomerulonephritis in allografted kidneys. Clin Nephrol 1977; 7(2):47-54.
206. Michielsen P. Recurrence of the original disease. Does this influence renal graft failure? Kidney Int Suppl 1995; 52:S79-84.
207. Lien YH, Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. Am J Kidney Dis 2000; 35(3):539-543.
208. Brunt EM, Kissane JM, Cole BR et al. Transmission and resolution of type I membranoproliferative glomerulonephritis in recipients of cadaveric renal allografts. Transplantation 1988; 46(4):595-98.
209. Curschellas E, Landmann J, Durig M et al. Morphologic findings in “zero-hour” biopsies of renal transplants. Clin Nephrol 1991; 36(5):215-22.
210. Valenzuela R, Hamway SA, Deodhar SD et al. Histologie, ultrastructural and immunomicroscopic findings in 96 one hour human renal allograft biopsy specimens. Immunologic and clinical significance. Hum Pathol1980; 11(2):187-95.
211. Glicklich D, Matas AJ, Sablay LB et al. Recurrent membranoproliferative glomerulonephritis type 1 in successive renal transplants. Am J Nephrol 1987; 7(2):143-49.
212. Zimmerman SW, Hyman LR, Uehling DT et al. Recurrent membranoproliferative glomerulonephritis with glomerular properdin deposition in allografts. Ann Intern Med 1974; 80(2):l69-75.
213. Saxena R, Frankel WL, Sedmak DD et al. Recurrent type I membrano-proliferative glomerulonephritis in a renal allograft: successful treatment with plasmapheresis. Am J Kidney Dis 2000; 35(4):749-52.
214. Little MA, Dupont P, Campbell E et al. Response to /'Differences between type I and II membranoproliferative glomerulonephritis/’. Kidney Int 2006; 70(8):1527-27.
215. Welch TR, Beischel L, Balakrishnan K et al. Major-histocompatibility-complex extended haplotypes in membranoproliferative glomerulonephritis. N Engl J Med 1986; 314(23):1476-81.
216. Berthoux FC, Ducret F, Colon S et al. Renal transplantation in mesan-gioproliferative glomerulonephritis (MPGN): relationship between the high frquency of recurrent glomerulonephritis and hypocomplementemia. Kidney Int Suppl 1975; (3): 323-27.
217. Cahen R, Trolliet P, Dijoud F et al. Severe recurrence of type I mem-branoproliferative glomerulonephritis after transplantation: remission on steroids and cyclophosphamide. Transplant Proc 1995; 27(2): 1746-47.
218. Ahsan N, Manning EC, Dabbs DJ et al. Recurrent type I membranoproliferative glomerulonephritis after renal transplantation and protective role of cyclosporine in acute crescentic transformation. Clin Transplant1997; 11(1):9-14.
219. Tomlanovich S, Vincenti F, Amend W et al. Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease after renal transplantation? Transplant Proc 1988; 20(3 Suppl 4):285-88.
220. Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12(2):394-402.
221. Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 2003; 18(7): 1260-65
222. Masutani K, Katafuchi R, Ikeda H et al. Recurrent nephrotic syndrome after living-related renal transplantation resistant to plasma exchange: report of two cases. Clin Transplant 2005; 19 Suppl 14:59-64.
223. Wu J, Jaar BG, Briggs WA et al. High-dose mycophenolate mofetil in the treatment of posttransplant glomerular disease in the allograft: a case series. Nephron Clin Pract 2004; 98(3):c61-66.
224. Cantarell MC, Charco R, Capdevila L et al. Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after liver transplantation. Transplantation 1999; 68(8):1131-34.
225. Hiesse C, Samuel D, Bensadoun H et al. Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease. Nephrol Dial Transplant 1995; 10 Suppl6:129-33.
226. Andresdottir MB, Assmann KJ, Hoitsma AJ et al. Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. Nephrol Dial Transplant 1999;14(7): 1723-31.
227. Braun MC, Stablein DM, Hamiwka LA et al. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol 2005; 16(7):2225-33.
228. Fremeaux-Bacchi V, Weiss L, Brun P et al. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant 1994; 9(7):811-14.
229. Leibowitch J, Halbwachs L, Wattel S et al. Recurrence of dense deposits in transplanted kidney: II. Serum complement and nephritic factor profiles. Kidney Int 1971; 5(4): 396-403.
230. Habib R, Antignac C, Hinglais N et al. Glomerular lesions in the transplanted kidney in children. Am J Kidney Dis 1981; 10(3): 198-207.
231. Turner DR, Cameron JS, Bewick M et al. Transplantation in mesangio-capillary glomerulonephritis with intramembranous dense “deposits”: recurrence of disease. Kidney Int 1976; 9(5):439-48.
232. Aita K, Ito S, Tanabe K, Toma H et al. Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation. Pathol Int 2006; 56(2):101-9.
233. Joh K, Aizawa S, Matsuyama N et al. Morphologic variations of dense deposit disease: light and electron microscopic, immunohistochemical and clinical findings in 10 patients. Acta Pathol Jpn 1993; 43(10):552-65.
234. Silva F. Membranoprolifertive glomeulonephritis. Philadelphia: Lippincott-Raven, 1998.
235. Droz D, Nabarra B, Noel LH et al. Recurrence of dense deposits in transplanted kidneys: I. Sequential survey of the lesions. Kidney Int 1979; 15(4):386-95.
236. Bennett WM, Fassett RG, Walker RG et al. Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. Am J Kidney Dis 1989; 13(6):469-76.
237. Muller T, Sikora P, Ofiner G et al. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol 1998; 49(2):82-90.
238. Briner J. Glomerular lesions in renal allografts. Ergeb Inn Med Kinder-heilkd 1982; 49:1-76.
239. Eddy A, Sibley R, Mauer SM et al. Renal allograft failure due to recurrent dense intramembranous deposit disease. Clin Nephrol 1984; 21(6):305-13.
240. Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher 2002; 7(3): 135-37.
241. Oberkircher OR, Enama M, West JC et al. Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapheresis therapy. Transplant Proc 1988; 20(1 Suppl 1):418-23.
242. Strife CF, Jackson EC, McAdams AJ. Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clin Nephrol 1984; 21(6):323-34.
243. Morales JM, Martinez MA, Munoz de Bustillo E et al. Recurrent type III membranoproliferative glomerulonephritis after kidney transplantation. Transplantation 1997; 63(8):1186-88.
244. Ramesh Prasad GV, Shamy F, Zaltzman JS. Recurrence of type III membranoproliferative glomerulonephritis after renal transplantation. Clin Nephrol 2004; 61(1):80-81.
245. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculi-tides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2):187-92.
246. Weidemann S, Andrassy K, Ritz E. ANCA in haemodialysis patients. Nephrol Dial Transplant 1993; 8(9):839-45.
247. Lobbedez T, Comoz F, Renaudineau E et al. Recurrence of ANCA-positive glomerulonephritis immediately after renal transplantation. Am J Kidney Dis 2003; 42(4):E2-6.
248. Lowance DC, Vosatka K, Whelchel J, et al. Recurrent Wegener s granulomatosis. Am J Med 1992; 92(5):573-75.
249. Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-as-sociated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56(4): 1544-50.
250. Reaich D, Cooper N, Main J. Rapid catastrophic onset of Wegener s granulomatosis in a renal transplant. Nephron 1994; 67(3):354-57.
251. Deegens JK, Artz MA, Hoitsma AJ et al. Outcome of renal transplantation in patients with pauci-immune small vessel vasculitis or anti-GBM disease. Clin Nephrol 2003; 59(1):1-9.
252. Nyberg G, Akesson P, Norden G et al. Systemic vasculitis in a kidney transplant population. Transplantation 1997; 63(9):1273-77.
253. Nachman PH, Hogan SL, Jennette JC et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7(1):33-39.
254. Grotz W, Wanner C, Rother E et al. Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 1995; 69(3):234-36.
255. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9(7):1258-63.
256. Schmitt WH, Haubitz M, Mistry N et al. Renal transplantation in Wegeners granulomatosis. Lancet 1993; 342(8875):860.
257. Clarke AE, Bitton A, Eappen R et al. Treatment of Wegener’s granulomatosis after renal transplantation: is cyclosporine the preferred treatment?Transplantation 1990; 50(6): 1047-51.
258. Curtis JJ, Diethelm AG, Herrera GA et al. Recurrence of Wegeners granulomatosis in a cadaver renal allograft. Transplantation 1983; 36(4):452-54.
259. Oberhuber G, Prior C, Bosmuller C et al. Early recurrence of Wegener s granulomatosis in a kidney allograft under cyclosporine treatment. Transpl Int 1988; 1(1):49-50.
260. Turney JH, Adu D, Michael J et al. Recurrent crescentic glomerulonephritis in renal transplant recipient treated with cyclosporin. Lancet 1986; 1(8489):1104.
261. Adams PL, Iskandar SS, Rohr MS. Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft. Am J Kidney Dis 1999; 33(3):552-54.
262. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29(2):315-33.
263. Chang YJ, Spiera H. Renal transplantation in scleroderma. Medicine (Baltimore) 1999; 78(6):382-85.
264. Paul M, Bear RA, Sugar L. Renal transplantation in scleroderma. J Rheumatol 1984; 11(3):406-8.
265. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renalc failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11Suppl 7:4-20.
266. Haubitz M, Kliem V, Koch KM et al. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997; 63(9):1251-57.
267. Lockwood CM, Peters DK. Plasma exchange in glomerulonephritis and related vasculitides. Annu Rev Med 1980; 31:167-79.
268. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-stage renal failure—to transplant or not to transplant? Nephrol Dial Transplant1998; 13(6):1346-48.
269. Couscr WG, Wallace A, Monaco AP et al. Successful renal transplantation in patients with circulating antibody to glomerular basement membrane: report of two cases. Clin Nephrol 1973; 1(6):384-88.
270. Beleil OM, Cobum JW, Shinaberger JH et al. Recurrent glomerulonephritis due to anti-glomerular basement membrane-antibodies in two successive allografts. Clin Nephrol 1973; 1(6):377-80.
271. Dixon FJ, McPhaul JJ, Lerner RA. The contribution of kidney transplantation o the study of glomerulonephritis—the recurrence of glomerulonephritis in renal transplants. Transplant Proc 1969; 1(1): 194-96.
272. Khandelwal M, McCormick BB, Lajoie G et al. Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 2004; 19(2):491-94.
273. Persson U, Hertz JM, Wieslander J et al. Alport syndrome in southern Sweden. Clin Nephrol 2005; 64(2):85-90.
274. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15(10):2514-27.
275. Turner AN, Rees AJ. Goodpasture’s disease and Alports syndromes. Annu Rev Med 1996; 47:377-86.
276. Browne G, Brown PA, Tomson CR et al. Retransplantation in Alport posttransplant anti-GBM disease. Kidney Int 2004; 65(2):675-81.
277. Ding J, Zhou J, Tryggvason K et al. COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1994; 5(2):161-68.
278. Shah B, First MR, Mendoza NC et al. Alports syndrome: risk of glomerulonephritis induced by anti-glomerular-basement-membrane antibody after renal transplantation. Nephron 1988; 50(1):34-38.
279. Byrne MC, Budisavljevic MN, Fan Z et al. Renal transplant in patients with Alports syndrome. Am J Kidney Dis 2002; 39(4):769-75.
280. Brainwood D, Kashtan C, Gubler MC et al. Targets of alloantibodies in Alport anti-glomerular basement membrane disease after renal transplantation. Kidney Int 1998; 53(3):762-66.
281. Peten E, Pirson Y, Cosyns JP et al. Outcome of thirty patients with Alports syndrome after renal transplantation. Transplantation 1991; 52(5):823-26.
282. Gobel J, Olbricht CJ, Oflher G et al. Kidney transplantation in Alport’s syndrome: long-term outcome and allograft anti-GBM nephritis. Clin Nephrol 1992; 38(6):299-304.
283. Kailuri R, van den Heuvel LP, Smeets HJ et al. A COL4A3 gene mutation and posttransplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1995; 47(4):1199-204.
284. Hariharan S, Adams MB, Brennan DC et al. Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. Transplant Proc 1999; 31(1-2):223-24.